Please assess the completion status of the following clinical trial:

Trial Title: VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed endometrial carcinoma, meeting both of the following criteria:~  * Recurrent or persistent disease~ * Refractory to curative therapy or established treatments~* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan~  * Tumors within a previously irradiated field are designated as nontarget lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days after completion of radiotherapy~* Must have received one prior chemotherapeutic regimen for management of endometrial carcinoma (initial treatment may include high-dose therapy, consolidation therapy, or extended therapy administered after surgical or non-surgical assessment)~* Not a candidate for a higher priority GOG protocol~* No history or evidence of primary brain tumor or brain metastases~* GOG performance status (PS) 0-2 (patients who received 1 prior regimen) OR GOG PS 0-1 (patients who received 2 prior regimens)~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Urine protein:creatinine ratio \< 1.0 OR urine protein \< 1.0 g by 24-hour urine collection~* Creatinine ≤ 1.5 times upper limit of normal (ULN)~* Bilirubin ≤ 1.5 times ULN~* SGOT ≤ 2.5 times ULN~* Alkaline phosphatase ≤ 2.5 times ULN~* PT/PTT/INR ≤ 1.5 times ULN~  * In-range INR (between 2 and 3) allowed if patient is on a stable dose of therapeutic warfarin~* QTc \< 500 msec~* No evidence of serious ventricular arrhythmia~  * Ventricular tachycardia or ventricular fibrillation must be \< 3 beats in a row~* LVEF normal~  * Ejection fraction ≥ 50% (for patients who received prior anthracycline, including doxorubicin hydrochloride and/or doxorubicin hydrochloride liposome)~* No clinically significant cardiovascular disease, including any of the following:~  * Uncontrolled hypertension, defined as systolic blood pressure (BP) \> 140 mm Hg or diastolic BP \> 90 mm Hg~ * Myocardial infarction or unstable angina within the past 6 months~ * NYHA class II-IV congestive heart failure~ * Serious cardiac arrhythmia requiring medication~ * Peripheral vascular disease ≥ grade 2~ * Cerebrovascular accident (i.e., CVA or stroke), transient ischemic attack, or subarachnoid hemorrhage within the past 6 months~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for ≥ 6 months after completion of study therapy~* No HIV positivity~* No neuropathy (sensory and motor) \> grade 1~* No active infection requiring antibiotics~* No other invasive malignancies or any evidence of other cancer within the past 5 years except for nonmelanoma skin cancer~* No serious nonhealing wound, ulcer, or bone fracture~* No history of abdominal fistula or gastrointestinal perforation~* No history or evidence of seizures not controlled with standard medical therapy~* No intra-abdominal abscess within the past 28 days~* No active bleeding or pathologic conditions that carry a high risk of bleeding (e.g., bleeding disorder, coagulopathy, or tumor involving major vessels)~* No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies~* No significant traumatic injury within the past 28 days~* No concurrent combination antiretroviral therapy for HIV-positive patients~* Recovered from prior surgery~* More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy and recovered~* At least 1 week since prior hormonal therapy~  * Concurrent hormone replacement therapy allowed~* At least 3 weeks since any other prior therapy, including immunologic agents~* One additional prior cytotoxic regimen for management of recurrent or persistent endometrial cancer allowed~  * Cytotoxic regimens include any agent that targets the genetic and/or mitotic apparatus of dividing cells, resulting in dose-limiting toxicity to the bone marrow and/or gastrointestinal mucosa~* More than 28 days since prior major surgery or open biopsy~* More than 7 days since prior minor surgery, fine needle aspirates, or core biopsies~* No prior cancer treatment that would preclude study compliance~* No prior noncytotoxic chemotherapy for management of recurrent or persistent endometrial disease~* No prior VEGF Trap or other VEGF pathway-targeted therapy~* More than 5 years since prior radiotherapy to any portion of the abdominal cavity or pelvis except for the treatment of endometrial cancer~  * More than 3 years since prior radiotherapy for localized cancer of the breast, head and neck, or skin~    * Patient must remain free of recurrent or metastatic disease~* More than 5 years since prior chemotherapy for any abdominal or pelvic tumor except for the treatment of endometrial cancer~  * More than 3 years since prior adjuvant chemotherapy for localized breast cancer~    * Patient must remain free of recurrent or metastatic disease~* Concurrent low-molecular weight heparin allowed for the prevention or treatment of venous thromboembolic disease if condition is considered clinically stable with treatment~* No other concurrent investigational agents~* No concurrent major surgery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (aflibercept) (Type: EXPERIMENTAL): Patients receive VEGF Trap IV over 1 hour on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).